Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-02

Bristol Myers Squibb Co (BMY)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$21,879,919
Christopher Boerner total, FY2025
25th
CEO pay percentile vs peers
131:1
CEO-to-median pay ratio
94.84%
Say-on-pay support, latest vote
Companies that benchmark against BMY
24 companies name BMY as a compensation peer

Each company listed discloses BMY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BMY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Christopher Boerner$1,586,346$0$16,061,399$0$3,754,684$0$477,490$21,879,919
Board Chair and Chief Executive Officer
Samit Hirawat964,90405,815,3200928,65802,625,35110,334,233
Former EVP, Chief Medical Officer, Head of Development
Cristian Massacesi388,4621,125,0007,853,9940660,876044,61810,072,950
EVP, Chief Medical Officer, Head of Development
Adam Lenkowsky1,131,73106,136,80001,794,73227,060250,0299,340,352
EVP, Chief Commercialization Officer
David Elkins1,140,44205,981,51301,799,4840256,1519,177,590
EVP and Chief Financial Officer
Greg Meyers1,072,69204,209,16801,669,0360230,2777,181,173
EVP and Chief Digital & Technology Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Christopher Boerner$21,879,919$18,787,618$8,461,833+3,092,301
Samit Hirawat10,334,2338,586,0146,233,627+1,748,219
Cristian Massacesi10,072,950
Adam Lenkowsky9,340,352
David Elkins9,177,5908,707,5717,166,300+470,019
Greg Meyers7,181,173

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Phyllis R. YaleDirector2026-03-31A577.08$61$35,000Derivative, Class A CommonForm 4 ↗
Peter J. ArduiniDirector2026-03-31A577.086135,000Derivative, Class A CommonForm 4 ↗
Michael R. McMullenDirector2026-03-31A577.086135,000Derivative, Class A CommonForm 4 ↗
Theodore R. SamuelsDirector2026-03-31A845.016151,250Derivative, Class A CommonForm 4 ↗
Derica W. RiceDirector2026-03-31A638.916138,750Derivative, Class A CommonForm 4 ↗
Karin ShanahanEVP, Chief Supply Chain & Ops2026-04-01A3,30700CommonForm 4 ↗
David ElkinsEVP, Chief Financial Officer2026-04-01D4,48162278,046CommonForm 4 ↗
Karin ShanahanEVP, Chief Supply Chain & Ops2026-04-01D3,30700Derivative, Class A CommonForm 4 ↗
Karin ShanahanEVP, Chief Supply Chain & Ops2026-04-01D1,69262104,447CommonForm 4 ↗
David ElkinsEVP, Chief Financial Officer2026-04-01D25,519621,571,970CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01A1,37300CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01D5995834,874CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01D20300CommonForm 4 ↗
Dividend-equivalent accruals2026-05-011,3731 insider, 1 accrual row
Bartie Wendy ShortEVP, Corporate Affairs2026-06-03A8,04000CommonForm 4 ↗
Bartie Wendy ShortEVP, Corporate Affairs2026-06-03D8,04000Derivative, Class A CommonForm 4 ↗
Bartie Wendy ShortEVP, Corporate Affairs2026-06-03D3,87655212,095CommonForm 4 ↗
Julia A. HallerDirector2026-06-15D20,46000Derivative, Class A CommonForm 4 ↗
Julia A. HallerDirector2026-06-15A20,460541,099,930CommonForm 4 ↗
Theodore R. SamuelsDirector2026-06-30A889.455851,250Derivative, Class A CommonForm 4 ↗
Derica W. RiceDirector2026-06-30A672.515838,750Derivative, Class A CommonForm 4 ↗
Peter J. ArduiniDirector2026-06-30A607.435835,000Derivative, Class A CommonForm 4 ↗
Michael R. McMullenDirector2026-06-30A607.435835,000Derivative, Class A CommonForm 4 ↗
Phyllis R. YaleDirector2026-06-30A607.435835,000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 24 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Phyllis R. YaleDirector2026-03-31A577.08$61$35,000Derivative, Class A CommonForm 4 ↗
Peter J. ArduiniDirector2026-03-31A577.086135,000Derivative, Class A CommonForm 4 ↗
Michael R. McMullenDirector2026-03-31A577.086135,000Derivative, Class A CommonForm 4 ↗
Theodore R. SamuelsDirector2026-03-31A845.016151,250Derivative, Class A CommonForm 4 ↗
Derica W. RiceDirector2026-03-31A638.916138,750Derivative, Class A CommonForm 4 ↗
Karin ShanahanEVP, Chief Supply Chain & Ops2026-04-01A3,30700CommonForm 4 ↗
David ElkinsEVP, Chief Financial Officer2026-04-01D4,48162278,046CommonForm 4 ↗
Karin ShanahanEVP, Chief Supply Chain & Ops2026-04-01D3,30700Derivative, Class A CommonForm 4 ↗
Karin ShanahanEVP, Chief Supply Chain & Ops2026-04-01D1,69262104,447CommonForm 4 ↗
David ElkinsEVP, Chief Financial Officer2026-04-01D25,519621,571,970CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01A1,37300CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01D5995834,874CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01D20300CommonForm 4 ↗
Adam LenkowskyEVP, Chief Commercial Officer2026-05-01D1,37300Derivative, Class A CommonForm 4 ↗
Bartie Wendy ShortEVP, Corporate Affairs2026-06-03A8,04000CommonForm 4 ↗
Bartie Wendy ShortEVP, Corporate Affairs2026-06-03D8,04000Derivative, Class A CommonForm 4 ↗
Bartie Wendy ShortEVP, Corporate Affairs2026-06-03D3,87655212,095CommonForm 4 ↗
Julia A. HallerDirector2026-06-15D20,46000Derivative, Class A CommonForm 4 ↗
Julia A. HallerDirector2026-06-15A20,460541,099,930CommonForm 4 ↗
Theodore R. SamuelsDirector2026-06-30A889.455851,250Derivative, Class A CommonForm 4 ↗
Derica W. RiceDirector2026-06-30A672.515838,750Derivative, Class A CommonForm 4 ↗
Peter J. ArduiniDirector2026-06-30A607.435835,000Derivative, Class A CommonForm 4 ↗
Michael R. McMullenDirector2026-06-30A607.435835,000Derivative, Class A CommonForm 4 ↗
Phyllis R. YaleDirector2026-06-30A607.435835,000Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Samit HirawatPSU52,720105,440$3,306,598
Adam LenkowskyPSU47,19794,3942,960,196
Greg MeyersPSU12,72025,43957,2381,815,836
David ElkinsPSU54,226108,4523,401,055
Cristian MassacesiRSU204,6917,853,994
Christopher BoernerPSU145,607291,2149,132,471
Samit HirawatPSU17,57335,14679,0792,508,721
David ElkinsPSU18,07636,15181,3402,580,458
Adam LenkowskyRSU22,568930,704
Greg MeyersPSU38,15976,3182,393,332
Adam LenkowskyPSU15,73231,46470,7942,245,900
Christopher BoernerPSU48,53697,071218,4106,928,928
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Samit Hirawat$0$5,815,319$0100.0%
Adam Lenkowsky930,7045,206,096084.8%
Greg Meyers04,209,1680100.0%
David Elkins05,981,5130100.0%
Cristian Massacesi7,853,994000.0%
Christopher Boerner016,061,3990100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Adam LenkowskyRSU2,198$118,582
Adam LenkowskyRSU15,732848,584
David ElkinsRSU62,6933,381,660
Samit HirawatRSU31,0551,675,107
David ElkinsRSU20,8981,127,238
Christopher BoernerRSU13,466726,356
Samit HirawatRSU11,180603,049
David ElkinsRSU7,654412,857
Adam LenkowskyRSU1,82898,602
Christopher BoernerRSU148,0267,984,522
Christopher BoernerRSU48,5362,618,005
Samit HirawatRSU33,5401,809,148
David ElkinsRSU54,2262,924,950
Adam LenkowskyRSU47,1972,545,806
Greg MeyersRSU38,1592,058,296
David ElkinsRSU15,808852,684
Samit HirawatRSU3,804205,161
Adam LenkowskyRSU31,3471,690,857
Cristian MassacesiRSU204,69111,041,033
Christopher BoernerRSU145,6077,854,042
Christopher BoernerRSU58,1863,138,553
Christopher BoernerRSU49,3422,661,507
David ElkinsRSU47,4242,558,051
Greg MeyersRSU29,0251,565,609
Adam LenkowskyRSU22,5681,217,318
Adam LenkowskyRSU20,2431,091,907
Greg MeyersRSU19,7601,065,854
David ElkinsRSU18,076974,992
Greg MeyersRSU12,720686,090
Greg MeyersRSU12,562677,594
Samit HirawatRSU11,411615,509
Adam LenkowskyRSU10,449563,619
Greg MeyersRSU9,675521,870
Christopher BoernerRSU6,618356,975
Greg MeyersRSU6,587355,303
Christopher BoernerRSU5,930319,864
Adam LenkowskyRSU4,001215,814
Greg MeyersRSU2,839153,136
Greg MeyersRSU2,543137,169
05

Incentive-plan design — the Compensation Discussion & Analysis

At Bristol Myers Squibb, the cornerstone of our compensation philosophy and program structure is aligning pay to the achievement of both our short-term and long-term goals, engagement of our employees, the achievement of our mission and the delivery of value to our shareholders.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantFarient Advisors LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-051,459,162,31072,490,0266,933,06194.84%Passed
20252025-05-061,443,673,10492,005,4195,809,87994.01%Passed
20242024-05-071,398,917,46182,961,6477,843,74194.4%Passed
20232023-05-021,438,045,960118,332,5986,881,09692.4%Passed
20222022-05-031,419,400,241125,669,1137,303,24791.87%Passed
20212021-05-041,450,442,588141,779,7587,252,27691.1%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-0594.84%a
20252025-05-0694.01%b
20242024-05-0794.4%c

a. Approved under the standard stated in the filing — “The affirmative vote of a majority of our outstanding shares present in person or by proxy and entitled to vote on the matter is required for the approval of the advisory vote to approve the compensation of our Named Executive Officers.”.

b. Approved under the standard stated in the filing — “How Will My Shares Be Voted at the Virtual Annual Meeting? Voting Options Item Proposal Voting Options Effect of Abstentions Broker Discretionary Voting Allowed? Effect of Broker Non-Votes 1 Election of Directors FOR, AGAINST or ABSTAIN (for each director nominee) No effect--not counted as a vote cast No No effect 2 Advisory vote to approve the compensation of our Named Executive Officers FOR, AGAINST or ABSTAIN Treated as a vote AGAINST the proposal No No effect 3 Ratification of the appointment of an independent registered public accounting firm FOR, AGAINST or ABSTAIN Treated as a vote AGAINST the proposal Yes Not applicable 4 Shareholder Proposal on Corporate Financial Sustainability FOR, AGAINST or ABSTAIN Treated as a vote AGAINST the proposal No No effect 5 Shareholder Proposal on a Request to Cease DEI Efforts FOR, AGAINST or ABSTAIN Treated as a vote AGAINST the proposal No No effect How Many Votes Are Needed to Elect the Directors and to Approve Each of the Proposals? Director Elections: A majority of votes cast with respect to each director's election at the meeting is required to elect each director.”.

c. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast for or against the director and broker non-votes will have no effect on this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)131 : 1
CEO total compensation$21,879,919
Median employee compensation$167,191
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Theodore R. SamuelsIndependent · Lead Independent Director · Committee on Directors and Corporate Governance (Chair) · Audit Committee$200,000$210,000$0$30,000$440,000
Derica W. RiceIndependent · Audit Committee (Chair) · Committee on Directors and Corporate Governance · Audit Committee(1) (Chair)150,000210,000030,000390,000
Julia A. Haller, M.DIndependent · Science & Technology Committee (Chair) · Committee on Directors and Corporate Governance150,000210,000030,000390,000
Paula A. PriceIndependent · Audit Committee · Committee on Directors and Corporate Governance140,000210,000030,000380,000
Michael R. McMullenIndependent · Audit Committee · Compensation and Management Development Committee134,966210,000030,000374,966
Peter J. ArduiniIndependent · Compensation and Management Development Committee (Chair)135,000210,000026,500371,500
Phyllis R. YaleIndependent · Audit Committee · Science & Technology Committee140,000210,000020,000370,000
Karen H. Vousden, Ph.DIndependent · Science & Technology Committee · Committee on Directors and Corporate Governance140,000210,00006,000356,000
Deepak L. Bhatt, M.D., M.P.H., M.B.AIndependent · Science & Technology Committee · Compensation and Management Development Committee140,000210,00000350,000
Manuel Hidalgo Medina, M.D., Ph.DIndependent · Committee on Directors and Corporate Governance · Science & Technology Committee140,000210,00000350,000
Christopher S. Boerner, Ph.DEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$110,000
Annual equity retainer$210,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 25,000 / 25,000
Stock ownership guideline5x annual cash retainer ($550,000)
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,469,966
Equity awards (grant-date value)$2,100,000
All other compensation$202,500
Total cost of the board$3,772,466

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

TAK Takeda Pharmaceutical Co.AMGN Amgen Inc.PFE Pfizer Inc.AZN AstraZeneca PLCJNJ Johnson & JohnsonABBV AbbVie Inc.LLY Eli Lilly and CompanyREGN Regeneron PharmaceuticalsGSK GlaxoSmithKline PLCNVS Novartis AGSNY SanofiMRK Merck & Co.GILD Gilead Sciences Roche Holding AG
10a

Peer reciprocity

Of the companies Bristol Myers Squibb Co names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Takeda Pharmaceutical Co. (TAK) Amgen Inc. (AMGN)70 Pfizer Inc. (PFE)71 AstraZeneca PLC (AZN) Johnson & Johnson (JNJ)72 AbbVie Inc. (ABBV)73 Eli Lilly and Company (LLY)74 Regeneron Pharmaceuticals (REGN)75 GlaxoSmithKline PLC (GSK) Novartis AG (NVS) Sanofi (SNY) Merck & Co. (MRK)76 Gilead Sciences (GILD)77

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Bristol Myers Squibb Co.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eli Lilly and Company2025David Ricks$1,700,000$23,325,000$0$6,485,500$36,698,337
2Johnson & Johnson2025Joaquin Duato1,600,00015,028,9485,927,9954,298,70032,758,111
3AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
4Gilead Sciences2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
5Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
6Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
7Bristol Myers Squibb Co2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
8Merck & Co.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
9Regeneron Pharmaceuticals2025Leonard Schleifer1,979,922003,682,6557,280,549
Takeda Pharmaceutical Co.not in coverage universe
AstraZeneca PLCnot in coverage universe
GlaxoSmithKline PLCnot in coverage universe
Novartis AGnot in coverage universe
Sanofinot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Bristol Myers Squibb Co157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
AbbVie Inc.not disclosedPSU 40 · RSU 40 · Options 20Yes — Relative TSRSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
AstraZeneca PLCnot disclosednot disclosednot disclosednot disclosed
Eli Lilly and Company218%PSU 100NoFW Cook
Gilead Sciences180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
GlaxoSmithKline PLCnot disclosednot disclosednot disclosednot disclosed
Johnson & Johnsonnot disclosednot disclosednot disclosedSemler Brossy Consulting Group
Merck & Co.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Novartis AGnot disclosednot disclosednot disclosednot disclosed
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
Regeneron Pharmaceuticals155%Options 60 · RSA 40not disclosedPay Governance LLC
Sanofinot disclosednot disclosednot disclosednot disclosed
Takeda Pharmaceutical Co.not disclosednot disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Bristol Myers Squibb Co in fiscal 2025?
The highest-paid executive was Christopher Boerner, Board Chair and Chief Executive Officer, with total compensation of $21,879,919.
How does Bristol Myers Squibb Co's chief executive pay compare to its disclosed peer group?
The CEO's pay was at the 25th percentile of the disclosed peer group.
What is Bristol Myers Squibb Co's CEO-to-median employee pay ratio?
The CEO-to-median employee pay ratio was 131:1.
How did shareholders vote on Bristol Myers Squibb Co's executive compensation?
Shareholders voted 94.84% in favor of the executive compensation plan.
How much does Bristol Myers Squibb Co spend in total on board compensation for fiscal 2025?
Total board compensation for fiscal 2025 was $3,772,466.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Christopher BoernerDEF 14A2026-03-250000014272-26-000006Section “Executive Compensation Tables” · page 79. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
2Section 01, Samit HirawatDEF 14A2026-03-250000014272-26-000006Section “Executive Compensation Tables” · page 79. As printed: 10,334,233. Filing ↗machine: t168 · r12 · c15 · span 1328162–1328172
3Section 01, Cristian MassacesiDEF 14A2026-03-250000014272-26-000006Section “Executive Compensation Tables” · page 79. As printed: 10,072,950. Filing ↗machine: t168 · r9 · c15 · span 1318889–1318899
4Section 01, Adam LenkowskyDEF 14A2026-03-250000014272-26-000006Section “Executive Compensation Tables” · page 79. As printed: 9,340,352. Filing ↗machine: t168 · r10 · c15 · span 1321707–1321716
5Section 01, David ElkinsDEF 14A2026-03-250000014272-26-000006Section “Executive Compensation Tables” · page 79. As printed: 9,177,590. Filing ↗machine: t168 · r6 · c15 · span 1310715–1310724
6Section 01, Greg MeyersDEF 14A2026-03-250000014272-26-000006Section “Executive Compensation Tables” · page 79. As printed: 7,181,173. Filing ↗machine: t168 · r11 · c15 · span 1324845–1324854
7Section 03, Samit Hirawat PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r21 · c15 · span 1428081–1428090
8Section 03, Adam Lenkowsky PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r14 · c14 · span 1411679–1411688
9Section 03, Greg Meyers PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
10Section 03, David Elkins PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r9 · c15 · span 1400364–1400373
11Section 03, Cristian Massacesi RSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r12 · c16 · span 1407567–1407576
12Section 03, Christopher Boerner PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r6 · c14 · span 1393484–1393493
13Section 03, Samit Hirawat PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
14Section 03, David Elkins PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
15Section 03, Adam Lenkowsky RSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t177 · r29 · c2 · span 1481013–1481019
16Section 03, Greg Meyers PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t174 · r18 · c14 · span 1420984–1420993
17Section 03, Adam Lenkowsky PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
18Section 03, Christopher Boerner PSUDEF 14A2026-03-250000014272-26-000006Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
19Section 07, pay ratioDEF 14A2026-03-250000014272-26-000006Section “CEO Pay Ratio”. As printed: 131 : 1. Filing ↗machine: span 1715416–1715419
20Section 08, Theodore R. SamuelsDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 440,000. Filing ↗machine: t79 · r10 · c10 · span 657387–657394
21Section 08, Derica W. RiceDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 390,000. Filing ↗machine: t79 · r9 · c10 · span 655299–655306
22Section 08, Julia A. Haller, M.DDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 390,000. Filing ↗machine: t79 · r5 · c10 · span 646939–646946
23Section 08, Paula A. PriceDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 380,000. Filing ↗machine: t79 · r8 · c10 · span 653214–653221
24Section 08, Michael R. McMullenDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 374,966. Filing ↗machine: t79 · r7 · c10 · span 651128–651135
25Section 08, Peter J. ArduiniDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 371,500. Filing ↗machine: t79 · r3 · c10 · span 642732–642739
26Section 08, Phyllis R. YaleDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 370,000. Filing ↗machine: t79 · r12 · c10 · span 661918–661925
27Section 08, Karen H. Vousden, Ph.DDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 356,000. Filing ↗machine: t79 · r11 · c10 · span 659481–659488
28Section 08, Deepak L. Bhatt, M.D., M.P.H., M.B.ADEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 350,000. Filing ↗machine: t79 · r4 · c10 · span 644846–644853
29Section 08, Manuel Hidalgo Medina, M.D., Ph.DDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 350,000. Filing ↗machine: t79 · r6 · c10 · span 649039–649046
30Section 08, Christopher S. Boerner, Ph.DDEF 14A2026-03-250000014272-26-000006Section “Director Compensation”. As printed: 0. Filing ↗
31Section 02, Phyllis R. Yale 2026-03-31Form 42026-04-020001269070-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Peter J. Arduini 2026-03-31Form 42026-04-020001323134-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Michael R. McMullen 2026-03-31Form 42026-04-020001418949-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Theodore R. Samuels 2026-03-31Form 42026-04-020001688276-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Derica W. Rice 2026-03-31Form 42026-04-020001359067-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Karin Shanahan 2026-04-01Form 42026-04-020001917325-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, David Elkins 2026-04-01Form 42026-04-020001451604-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Karin Shanahan 2026-04-01Form 42026-04-020001917325-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Karin Shanahan 2026-04-01Form 42026-04-020001917325-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, David Elkins 2026-04-01Form 42026-04-020001451604-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Adam Lenkowsky 2026-05-01Form 42026-05-050001975719-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Adam Lenkowsky 2026-05-01Form 42026-05-050001975719-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Adam Lenkowsky 2026-05-01Form 42026-05-050001975719-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Adam Lenkowsky 2026-05-01Form 42026-05-050001975719-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Bartie Wendy Short 2026-06-03Form 42026-06-050002070839-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Bartie Wendy Short 2026-06-03Form 42026-06-050002070839-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Bartie Wendy Short 2026-06-03Form 42026-06-050002070839-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Julia A. Haller 2026-06-15Form 42026-06-160001656082-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Julia A. Haller 2026-06-15Form 42026-06-160001656082-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Theodore R. Samuels 2026-06-30Form 42026-07-020001688276-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Derica W. Rice 2026-06-30Form 42026-07-020001359067-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Peter J. Arduini 2026-06-30Form 42026-07-020001323134-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Michael R. McMullen 2026-06-30Form 42026-07-020001418949-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Phyllis R. Yale 2026-06-30Form 42026-07-020001269070-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
55Section 06, 2026 voteForm 8-K2026-05-080001140361-26-020036Item 5.07 · say-on-pay result. As reported: 94.84% (votes for as printed: 1,459,162,310). Filing ↗
56Section 06, 2025 voteForm 8-K2025-05-070001140361-25-017742Item 5.07 · say-on-pay result. As reported: 94.01% (votes for as printed: 1,443,673,104). Filing ↗
57Section 06, 2024 voteForm 8-K2024-05-090001140361-24-025213Item 5.07 · say-on-pay result. As reported: 94.4% (votes for as printed: 1,398,917,461). Filing ↗
58Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
59Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
60Section 09b board cost (computed)ComputedcomputedCash 1,469,966 + equity 2,100,000 + all other 202,500 = 3,772,466, summed across the director compensation table rows.machine: formula: Σ = 3,772,466
61Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
62Johnson & Johnson, Section 10b CEO totalDEF 14A2026-03-110000200406-26-000063CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
63AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093
64Gilead Sciences, Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences's own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
65Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
66Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
67Bristol Myers Squibb Co (subject), Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol Myers Squibb Co's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
68Merck & Co., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
69Regeneron Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals's own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
70Section 10a, Amgen Inc. reciprocityDEF 14A0001193125-26-145588Amgen Inc. names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
71Section 10a, Pfizer Inc. reciprocityDEF 14A0000078003-26-000033Pfizer Inc. names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
72Section 10a, Johnson & Johnson reciprocityDEF 14A0000200406-26-000063Johnson & Johnson names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
73Section 10a, AbbVie Inc. reciprocityDEF 14A0001104659-26-033387AbbVie Inc. names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
74Section 10a, Eli Lilly and Company reciprocityDEF 14A0000059478-26-000029Eli Lilly and Company names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
75Section 10a, Regeneron Pharmaceuticals reciprocityDEF 14A0001308179-26-000340Regeneron Pharmaceuticals names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
76Section 10a, Merck & Co. reciprocityDEF 14A0001193125-26-147704Merck & Co. names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
77Section 10a, Gilead Sciences reciprocityDEF 14A0001308179-26-000106Gilead Sciences names Bristol Myers Squibb Co in its own disclosed peer group (read from its most recent proxy). Filing ↗